Reviews/Dry Eye Disease Treatment/Punctal plugs increase Schirmer test scores
Punctal Occlusion · DED-POC-02 · v2
Across several separate studies, people with dry eye tended to show more wetting on the Schirmer tear strip after punctal plugs were placed, and the direction of that change was consistent from one study to the next. Randomized trials [6][7], a trial that compared plugs against drops [10], a non-randomized comparison [4], a prospective series [11] and a large five-year record [12] all point the same way. The picture is not unanimous, though: two studies that measured the Schirmer test did not list it among the things that improved [1][5], and in one large cohort the graft-versus-host subgroup showed no change [9]. Most of the positive studies also had no untreated comparison group, so the rise cannot be cleanly separated from other treatments or natural recovery. The panel treated the signal as real and repeatedly observed but held back from calling it settled because of those gaps.
Multiple independent primary studies report higher Schirmer scores after punctal plugs. Two randomized trials show within-group improvement [6][7], a controlled trial in anophthalmic socket syndrome found Schirmer improved and favoured occlusion over tears [10], and a non-randomized comparison reported Schirmer values improved in both arms including plugs [4]. A prospective series in Sjögren and non-Sjögren patients found Schirmer improving in both groups [11], and a 302-patient retrospective recorded a Schirmer rise from 4.20 to 9.01 [12]. A 864-patient cohort found Schirmer improved in non-graft-versus-host patients [9]. The contested point: The division is over whether the rise is universal and attributable to the plug. Two studies that measured Schirmer did not report it improving [1][5], the graft-versus-host subgroup showed no change [9], and the strongest positive results lack an untreated control [4][6][7][11][12], so the panel split on how far the consistent direction can be generalised.
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The strongest Schirmer-positive results ([4],[6],[7],[11],[12]) are within-group or plug-vs-plug with no untreated control; the only true-control trials are [2] (no Schirmer measured) and [10] (anophthalmic socket, not DED). Within-group rises could reflect concomitant artificial-tear use or natural course rather than the plug.
Selective/absent reporting: [1] and [5] both measured Schirmer but omit it from their lists of significant improvements, consistent with a null effect that is under-reported and undercutting any claim of a universal increase.
Where it remains uncertain. Two trials that measured Schirmer did not report it improving [1][5], the oGVHD subgroup showed no change [9], and most positive studies had no untreated control [4][6][7][11][12].
Aleatory
The randomized trials are small (24 to 50 eyes) with heterogeneous plug types and follow-up from 2 weeks to 5 years [6][7][13], so sampling noise is large.
Epistemic
The strongest Schirmer-positive studies are within-group or plug-versus-plug with no no-treatment arm [4][6][7][11][12]; the true-control trials either measured no Schirmer [2] or were in a non-DED population [10].
Inferential
Plugs occlude tear drainage, so higher Schirmer strip wetting may reflect tear retention rather than increased lacrimal secretion, making the endpoint an indirect measure of production.
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Comparative study shows Schirmer improvement in the silicone-plug arm.
“Schirmer test values improved considerably ( P <0.05) without intergroup differences.”
Panel auditInternal validity: low · scope of inference: Moderate-to-severe bilateral DED in patients aged 44–74, plugs vs PRP over 3 months.Key limitations: nonrandomized · no placebo/untreated control · both-arm improvement not plug-specific
Double-masked RCT directly reports within-group Schirmer improvement after plugs.
“There was a statistically significant improvement in all secondary outcome measures (Schirmer, tear meniscus height, tear break-up time, fluorescein corneal staining) at 6 months within plug groups except conjunctival staining.”
Panel auditInternal validity: medium · scope of inference: Moderate-to-severe dry eye, two plug designs, 6-month within-group change.Key limitations: no untreated control for Schirmer · trial designed around retention · within-group comparison
Randomized trial reports significant Schirmer I improvement in both plug arms.
“In both patient groups, Schirmer I results, tear break-up times, and rose bengal staining scores improved significantly after plug insertion.”
Panel auditInternal validity: medium · scope of inference: Dry eye patients, collagen vs silicone plugs, short-term efficacy.Key limitations: small sample · short-term only · within-group pre/post for Schirmer
The abstract lists Schirmer among the tests performed but reports result changes only for symptom scoring, TBUT, fluorescein and rose Bengal — the Schirmer outcome is never stated.
Panel auditInternal validity: medium · scope of inference: Dry eye patients with TBUT <5s and surface damage, comparing two plug types over ~11 weeks.Key limitations: Schirmer result not reported · small sample · no untreated control · short follow-up
4 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Converging RCT and cohort evidence supports a Schirmer increase, but absent controls, two near-null reports and drainage-vs-production indirectness keep it short of Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No untreated control in classic DED. Within-group rises [4][6][7][11][12] cannot be separated from artificial-tear use or natural course without a no-treatment arm. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized trial in classic dry eye with a true no-treatment or sham control and Schirmer as a pre-specified primary endpoint.
Open question: Does Schirmer increase after punctal plugs when compared against a true untreated or sham control in classic dry eye? Why it is still open: The sham-controlled trial measured no Schirmer [2] and the controlled trial reporting Schirmer was in a non-DED population [10]; all other positive studies lacked an untreated arm [4][6][7][11][12].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19